fbpx Skip to main content

Artificial intelligence models have the capacity to provide screening and early detection for patients with AMD, although the technology is still in development. This article summarizes findings related to the training of artificial intelligence models to stratify wet AMD and make predictions on the outcome that a given patient may face.

The data used to train the artificial intelligence system were taken from the Age-related Eye Disease Study (AREDS). Further external validation was taken from the Nutritional AMD Treatment-2 (NAT-2) study. The deep learning screening methods were trained on 116,875 color fundus photos from 4,129 patients with AMD. The cases were stratified into no, early, intermediate, and advanced AMD.

These scores were then combined with social and demographic information and other extracted imaging data to predict the risk of progression of AMD within 1-2 years. The training was done using 923 AREDS participants who progressed after two years, 901 after one year, and 2,840 who did not progress after two years. Among patients who were predicted to progress, the type of AMD (dry vs. wet) was also predicted.

The outcomes achieved differing degrees of accuracy. The lowest was 67.15% for late wet AMD, and the highest was 99.2% accuracy for the initial stratification of AMD. The researchers concluded that these success rates are evidence that validated color fundus photo-based models are ready for clinical testing. These models have the potential to provide telemedical access to populations that are normally unable to receive diagnostic tests as easily [1].


[1] Bhuiyan, A., Wong, T. Y., Ting, D. S. W., Govindaiah, A., Souied, E. H., & Smith, R. T. (2020). Artificial Intelligence to Stratify Severity of Age-Related Macular Degeneration (AMD) and Predict Risk of Progression to Late AMD. Translational Vision Science & Technology, 9(2), 25. https://doi.org/10.1167/tvst.9.2.25

You May Also Like::  Dr. Murtaza Adam: Wet AMD, Treatment Barriers, and COVID-19

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More